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Abstract
Background Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence 
rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment 
failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease.
Objective This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile 
infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and 
other organisms.
Methods The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative 
cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole 
and vancomycin.
Results Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell 
density by 50–70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-
inferior to that of metronidazole and vancomycin.
Conclusions Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic 
option for the treatment of C. difficile infection.
Key Points 
Auranofin exhibits strong antimicrobial activity against 
Clostridium difficile.
Concentrations of auranofin as low as 4.07 µg/mL dem-
onstrated bactericidal and sporicidal activity against C. 
difficile.
1 Introduction
The Gram-positive, anaerobic bacterium Clostridium dif-
ficile is the leading cause of healthcare-associated diar-
rhea [1]. Clostridium difficile infection (CDI) is a signifi-
cant cause of morbidity and mortality among hospitalized 
patients [1]. Clostridium difficile infection can present as 
mild-to-moderate diarrhea through to more severe pseu-
domembranous colitis. Serious complications can be life 
threatening [1].
Infection with C. difficile is through the ingestion of 
spores via the nasogastric route, and is typically associated 
with antibiotic use [2]. Antibiotics deplete the intestinal 
microbiota, creating the ideal environment for C. difficile 
spores to germinate into vegetative cells [2–4]. The vegeta-
tive cells then colonise the gut mucosa and proliferate and 
produce more spores, as well as the primary virulence fac-
tors toxin A (TcdA) and toxin B (TcdB) [3–5].
Further disruption of the intestinal microbiota occurs dur-
ing treatment of CDI with the antibiotics, metronidazole or 
vancomycin [2]. While these antibiotics have been effec-
tive in the past, reports of treatment failures as high as 38% 
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indicate that these therapies are no longer adequate and new 
options are needed [6–8]. Newer antibiotic options such as 
fidaxomycin and rifaximin are recommended as alternatives 
to metronidazole and vancomycin [8, 9]. There have been 
reports of resistance to these antibiotics, further highlighting 
the need for other treatment options [10, 11].
One drug that has gained significant attention as a poten-
tial therapy for CDI is auranofin, a previously approved 
treatment for rheumatoid arthritis [11–13]. Auranofin has 
more recently been investigated as a treatment for a num-
ber of diseases including cancer, human immunodeficiency 
virus, parasitic infections such as Leishmaniasis, and infec-
tions caused by bacteria such as Staphylococcus aureus, 
Treponemia denticola, and C. difficile [12, 13]. Auranofin 
is poorly absorbed via the gastrointestinal tract, thus it has 
the ideal pharmacokinetics to treat CDI. Up to 85% of the 
administered dose will reach the distal colon [14], indicating 
that auranofin may be able to reach therapeutic concentra-
tions at the site of infection [2, 14].
Auranofin (2,3,4,6-tetra-o-acetyl-1-thio-b-d-glucopyrano-
sato-S-(triethylphosphine) gold) has been shown to inhibit 
the activity of reduction/oxidation (redox) enzymes, such 
as thioredoxin reductase, which are essential to many cel-
lular processes, including maintaining intracellular levels of 
reactive oxygen species [13]. This activity is due to the thiol 
ligand (Au-SH) in auranofin, which is able to form a stable 
adduct with thiol (R-SH) and selenol (R-SeH) ligands in 
these redox enzymes [13]. Auranofin also has a high affinity 
for inorganic selenium in the form of selenide  (HSe−), which 
makes auranofin particularly potent towards selenium-uti-
lising organisms such as C. difficile [1, 13]. Through the 
displacement of sulfur with selenium in the auranofin thiol 
ligand, selenium is removed from the environment, and 
thus unable to be utilised by C. difficile. As C. difficile has 
energy-conserving pathways that depend on selenium-uti-
lising enzymes called selenoproteins (i.e., glycine reductase 
and proline reductase), inorganic selenium is an essential 
micronutrient for this organism [1, 12, 13, 15, 16].
Previous studies by Jackson-Rosario et al. have demon-
strated that auranofin can prevent the growth of four C. dif-
ficile strains when treated at the time of inoculation with 
concentrations as low as 1.36 µg/mL [1]. They also dem-
onstrated that the addition of an alternate selenium source, 
such as selenite or l-selenocysteine, reduced the inhibitory 
activity of auranofin [1]. Further supporting the proposed 
mechanism of action, Jackson-Rosario et al. demonstrated 
that auranofin prevented the uptake of radioisotope selenium 
(75Se) by the bacteria, which in turn decreased selenopro-
tein synthesis [1]. More recently, AbdelKhalek et al. demon-
strated that at a minimum inhibitory concentration of 4 µg/
mL, auranofin inhibited bacterial growth. This activity was 
comparable to that of vancomycin and metronidazole [11]. 
They also demonstrated a dose-dependent inhibition of toxin 
synthesis and observed that auranofin protected intestinal 
epithelial cells from the inflammatory effects of the toxins 
in an in vitro model [11].
A limitation of both these studies was that they used 
freshly inoculated C. difficile culture, thus the effects they 
observed were on a culture that was in a lag and/or expo-
nential growth phase, not a culture that was in a stationary 
phase. From a clinical perspective, the symptoms of CDI 
are caused by TcdA and TcdB [3–5]. These toxins are not 
produced until the bacteria are in the stationary growth 
phase [3–5]. Auranofin needs to be tested against a culture 
in this growth phase to determine the antimicrobial activity 
of auranofin against a clinically relevant model and to deter-
mine the effects auranofin may have on spores.
This study further assesses auranofin as a treatment for 
CDI by testing the activity of auranofin on established C. 
difficile cultures using in vitro methods. It is hypothesized 
that auranofin will effectively inhibit C. difficile growth and 
reduce vegetative cell viability without promoting sporula-
tion and will be non-inferior to the current treatments for 
CDI.
2  Methods
2.1  Routine Bacterial Culture
The strain used was C. difficile M7404, which was stored 
in a glycerol stock at − 80 °C (MHB, 30% glycerol). When 
removed from storage, isolates were streaked for single 
colonies on brain heart infusion (BHI; Oxoid, Hampshire, 
England) agar with 0.1% (w/v) taurocholic acid sodium 
salt hydrate (Sigma-Aldrich, Castle Hill, NSW, Australia) 
to allow for spore germination. Broth cultures were grown 
in Tryptone yeast extract [3]. All bacterial work, includ-
ing incubation periods, were undertaken in a Don Whitley 
DG250 Workstation (Don Whitely Scientific, Gosford, 
NSW, Australia) to maintain an anaerobic environment (10% 
 H2, 10%  CO2 in  N2; BOC, NSW, Australia) and a tempera-
ture of 37 °C with 75% humidity [3]. All media were anaero-
bically conditioned prior to use by overnight incubation.
2.1.1  Preparation of Antibiotic Stock Solutions
Stock solutions of auranofin (Enzo, United Biosciences, 
Carindale, QLD, NSW, Australia) 4005.9 mg/L, metro-
nidazole (Sigma-Aldrich) 171.15 mg/L, and vancomycin 
hydrochloride (Sigma-Aldrich) 4999.9 mg/L were prepared 
by dissolving a powdered antibiotic in either 100% ethanol 
(Chem-supply, Westlabs, Mitchell Park, VIC, Australia) for 
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auranofin or sterile deionised water for metronidazole and 
vancomycin.
2.1.2  Bacterial Growth Assays (n = 3)
For each assay, 40 mL of Tryptone yeast broth was inocu-
lated with 1% (v/v) overnight culture of C. difficile M7404 
with optical density  (OD600nm) of 0.2 and incubated as 
described above. Treatments were applied at 12 h, which is 
the end of the exponential growth phase. Treatment groups 
were auranofin at 4.07 µg/mL, 33.97 µg/mL, 169.87 µg/
mL, and 339.75 µg/mL, the diluent ethanol at a percent-
age equivalent to that in the auranofin 33.97 µg/mL treat-
ment (0.8%), metronidazole 2.74 µg/mL, and vancomycin 
11.59 µg/mL. The control group was untreated C. difficile 
culture. Bacterial growth was measured using  OD600nm at 0, 
2 4, 6, 8, 10, 12, 14, 24, and 48 h with an Epoch 2 microplate 
reader (Biotek, Millennium Biosciences,  Mulgrave, VIC, 
Australia). Statistical analyses were performed using a two-
tailed unpaired t test with a 95% confidence interval.
2.2  Viable Cell Counts and Viable Spore Counts
Cell viability was assessed by viable cell counts (VCC) 
performed from samples taken at 0, 12, 24, and 48 h from 
the growth assay described above. Samples taken at each of 
these timepoints were serially diluted and 100 µL of each 
dilution from neat to  10−5 were inoculated onto BHI agar 
and incubated for 48 h. Colonies on each plate were then 
counted and the average colony-forming unit (CFU) was 
calculated.
Spore viability was assessed by viable spore counts 
(VSC), the method of which is similar to VCC with the fol-
lowing changes. First, the vegetative cells were heat killed at 
75 °C for 30 min, and second, the BHI agar contained 0.1% 
(w/v) taurocholic acid sodium salt hydrate to germinate the 
spores. Control samples were also inoculated onto BHI to 
confirm the heat killing of the vegetative cells.
2.3  Statistical Analysis
The statistical test used for each analysis is reported in the 
results. The relative change is defined as the difference 
between the final value and the initial value divided by the 
initial value, with a onefold change equivalent to a 100% 
change.
3  Results
3.1  Minimum Inhibitory Concentration of Auranofin
Experiments to determine the minimum inhibitory con-
centration (MIC) were consistent with those reported 
by AbdelKhalek et al., with the MIC for auranofin being 
4.07 µg/mL (data not shown). Sub-inhibitory concentra-
tions (< 67.84 ng/mL) did not promote sporulation (data 
not shown).
As shown in Fig. 1, when treated at stationary growth 
phase, C. difficile cultures treated with 4.07  µg/mL of 
auranofin showed a reduction in bacterial cell density of 
0.7-fold. The ethanol-treated and control cultures showed 
a 0.3-fold and a 0.5-fold increase in bacterial cell density, 
respectively (data are shown in Table 1).
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Fig. 1  Bacterial growth of Clostridium difficile cultures treated with 
auranofin and ethanol. Auranofin-treated cultures are shown by a 
solid line and filled triangles, ethanol-treated cultures are shown by 
a small dashed line and a filled circle, and untreated control cultures 
are shown by a large dashed line and filled squares. The arrow at 10 h 
indicates the time of treatment with either auranofin 33.97 mg/L or 
0.8% ethanol. ***p < 0.0005, n = 3. OD optical density
Table 1  Optical density  (OD600nm) of Clostridium difficile cultures 
treated with auranofin
Culture treatment Treatment 
timepoint
End timepoint Relative change
Auranofin 6 µM 0.37 0.087 − 0.7
0.8% ethanol 0.417 0.573 0.3
Control 0.46 0.687 0.5
Auranofin 50 µM 0.095 0.043 − 0.5
Auranofin 250 µM 0.091 0.052 − 0.5
Auranofin 500 µM 0.089 0.054 − 0.5
Control 0.085 0.086 0.01
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3.2  Treatment Concentrations of Auranofin
Treatment concentrations of 33.97 µg/mL, 169.87 µg/mL, 
and 339.75 µg/mL were compared to untreated control cul-
tures. The lower concentration (33.97 µg/mL) was chosen 
based on the results of the MIC titration assay (data not 
shown), while the highest concentration (339.75 µg/mL) 
was determined to be the maximum dose able to be used 
in a mouse model. The bacterial growth of these cultures is 
shown in Fig. 2. All three auranofin-treated cultures showed 
a significant onefold reduction in bacterial cell density com-
pared with the control, which showed a 0.01-fold increase in 
bacterial cell density (p < 0.0001, p < 0.001, and p = 0.003, 
respectively). There was no significant difference in the 
bacterial cell density between any of the auranofin-treated 
cultures. Data are shown in Table 1. The VCC and VSC 
from 12- and 24-h cultures are shown in Fig. 3. There was a 
onefold reduction in CFUs in all auranofin-treated cultures. 
The control culture showed a fourfold increase in CFUs. 
Similarly, the auranofin-treated cultures showed a onefold 
reduction in the spore counts, while the control showed a 
0.5-fold increase (data are shown in Table 2). 
3.3  Auranofin vs Metronidazole vs Vancomycin
The treatment concentrations used were based on MICs 
determined from microbroth dilution (data not shown). 
Additional timepoints of 36 and 60 h were added to accom-
modate the slow-acting antimicrobial activity of vancomy-
cin. Bacterial growth is shown in Fig. 4. The auranofin- and 
vancomycin-treated cultures both showed a 0.7-fold decrease 
in bacterial cell density between treatment (8 h) and 48 h. 
Overall, these cultures showed a 0.6-fold decrease in bacte-
rial cell density (8–60 h). Metronidazole had an initial 0.6-
fold decrease (8–36 h), and then showed a 0.8-fold increase 
(36–60 h). Overall, the metronidazole-treated cultures had 
a 0.2-fold decrease in bacterial cell density (8–60 h). The 
control cultures demonstrated an overall 0.4-fold decrease in 
bacterial cell density (8–60 h) [data are shown in Table 3].  
The VCC and VSC for 12, 24, and 48 h are shown in 
Fig.  5. For cell viability (VCC), auranofin-treated cul-
tures showed a onefold decrease in CFUs. The vancomy-
cin-treated cultures initially showed a 35-fold increase 
(12–24 h) followed by a 0.8-fold decrease (24–48 h) to 
have a 4.5-fold increase in CFUs overall. Metronidazole 
initially showed a onefold decrease (12–24 h) followed by 
a > 2000-fold increase (24–48 h) to have a 71-fold increase 
overall. The control group had a > 400-fold increase overall. 
The auranofin- and vancomycin-treated cultures had a CFU 
of < 30 for the VSC at all timepoints. At 48 h, the metroni-
dazole-treated cultures had a VSC of ~ 18,000 CFUs and the 
control had 116,000 CFUs.
4  Discussion
Clostridium difficile infection is an ongoing problem in the 
healthcare setting owing to the high rates of treatment failure 
and recurrent disease [3]. The threat of emerging resistance 
to antibiotics is also of great concern [10, 11]. This study 
aimed to demonstrate that auranofin could be repurposed 
as a treatment for CDI. This was achieved using an in vitro 
model that reflected an established infection.
Concentrations of auranofin as low as 4.07 µg/mL sig-
nificantly reduced the bacterial cell density of C. difficile 
cultures after they were treated at the beginning of the sta-
tionary growth phase. This is consistent with the observa-
tions made by AbdelKhalek et al., albeit at a later, more 
clinically relevant timepoint. Cultures treated with 33.97 µg/
mL or higher yielded no viable vegetative cells after the 
24-h timepoint, indicating that auranofin has bactericidal 
activity against C. difficile. This bactericidal activity makes 
auranofin a strong candidate for treatment of CDI.
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Fig. 2  Bacterial growth of Clostridium difficile cultures treated 
with auranofin. Treatment concentration of auranofin 33.97 mg/L is 
shown by a solid line with filled triangles, treatment concentration of 
auranofin 169.87  mg/L is shown by an alternating dashed line with 
unfilled triangles, treatment concentration of auranofin 339.75 mg/L 
is shown by a small dashed line with unfilled circles, and untreated 
cultures (control) are shown by a large dashed line with filled squares. 
The arrow at 12 h indicates the time of treatment. *Significant differ-
ence between cultures treated with auranofin 33.97 mg/L and the con-
trol, +significant difference between cultures treated with auranofin 
169.87  mg/L and the control, x indicates a significant difference 
between cultures treated with auranofin 339.75 mg/L and the control. 
All indicate a p value of < 0.005, n = 3. OD optical density
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Fig. 3  Number of viable vegetative cells and spores from Clostrid-
ium difficile cultures treated with auranofin. Vegetative cell viability 
assessed from C. difficile cultures at a 12  h post-inoculation and b 
24 h post-inoculation. Spore viability was assessed from C. difficile 
cultures at c 12 h post-inoculation and d 24 h post-inoculation. Treat-
ment concentration of auranofin 33.97  mg/L is shown by filled tri-
angles, treatment concentration of 169.87 mg/L is shown by unfilled 
triangles, treatment concentration of auranofin 339.75 mg/L is shown 
by unfilled circles, and untreated cultures (control) are shown by 
filled squares. *Significant difference between cultures treated with 
auranofin 33.97 mg/L and the control, +significant difference between 
cultures treated with auranofin 169.87 mg/L and the control, x indi-
cates a significant difference between cultures treated with auranofin 
339.75 mg/L and the control. *p < 0.05; **p < 0.005, n = 3. CFU col-
ony-forming unit
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Clostridium difficile spores are the transmissible element 
capable of causing widespread disease and are associated 
with recurrent infections [3, 4]. Auranofin was able to reduce 
the number of viable spores in C. difficile cultures after 
treatment. This suggests that auranofin may have sporicidal 
activity and can kill the spores, or has sporistatic activity 
and is able to prevent the germination of the spores into the 
vegetative form. This finding was beyond the expectations 
of the hypothesis and is highly significant. If auranofin were 
sporicidal, this would improve treatment outcomes, as there 
would be clearance of both forms of the bacteria, reducing 
the risk of the recurrence of CDI. It would also reduce trans-
mission of the organisms, thus limiting the spread of disease. 
It would be of interest to further investigate the extent of the 
effect auranofin has on C. difficile spores, particularly as the 
spores are highly resilient to the current therapies.
When compared to the current therapies, metronida-
zole and vancomycin, auranofin was found to be non-infe-
rior. There was no significant difference in the bacterial 
growth of C. difficile cultures treated with vancomycin 
or auranofin at any timepoint. Auranofin-treated cultures 
had less viable cells and spores from 24 h onwards than 
the cultures treated with either of the current therapies. 
Metronidazole-treated cultures initially showed a reduc-
tion in bacterial growth, but recovered after 24 h, indicat-
ing that a single dose of metronidazole was not able to 
sustain activity. This observation was reflected in the VCC 
and VSC, with high numbers of viable vegetative cells and 
spores from 48-h cultures.
Further in  vitro work is necessary to elucidate the 
mechanism by which auranofin is acting on C. difficile 
spores, followed by an in vivo animal model of CDI. It is 
also important to elucidate interactions between auranofin 
and the inflammation mediated by C. difficile toxins. 
AbdelKhalek et al. found that auranofin reduces the levels 
of the pro-inflammatory cytokine interleukin-8 by caco-2 
cells exposed to C. difficile toxins. Further work is needed 
in this area to fully understand this anti-inflammatory 
activity of auranofin. Additionally, the impact of auranofin 
on the intestinal microbiota should be investigated because 
intestinal dysbiosis due to antibiotic therapy is a key risk 
factor for recurrent CDI [3].
Table 2  Viable cell and viable spore counts of Clostridium difficile 
cultures treated with auranofin
VCC viable cell counts, VSC viable spore counts
Culture treatment 12 h (treatment) 24 h Relative change
VCC
 Auranofin 50 µM 56.6 × 106 53.33 − 1
 Auranofin 250 µM 71.3 × 106 75.3 × 104 − 1
 Auranofin 500 µM 11.8 × 106 1800 − 1
 Control 16.5 × 106 84.6 × 106 4
VSC
 Auranofin 50 µM 10,000 126 − 1
 Auranofin 250 µM 4866 33.33 − 1
 Auranofin 500 µM 7666 < 30 − 1
 Control 7666 11,866 0.5
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Fig. 4  Bacterial growth of Clostridium difficile cultures treated 
with auranofin, metronidazole, or vancomycin. Treatment with 
auranofin 4.08 mg/L (AS)  is shown by a solid line with filled trian-
gles, treatment with metronidazole 2.74  mg/L  (MS) is shown by a 
small dashed line with unfilled triangles, treatment with vancomy-
cin 11.59  mg/L  (VS) is shown by an alternating dashed line with 
unfilled circles, and untreated cultures (control; C) are shown by a 
large dashed line with filled squares. *Significant difference between 
cultures treated with auranofin and the control, +significant difference 
between cultures treated with vancomycin and the control, x indicates 
a significant difference between cultures treated with metronidazole 
and the control. All indicate a p value of < 0.005, n = 3. AS, C, MS, 
OD optical density, VS 
Table 3  Optical density  (OD600nm) of Clostridium difficile cultures 
treated with auranofin, vancomycin, or metronidazole
Treatment 8 h (treatment) 36 h 48 h 60 h Overall 
relative 
change
Auranofin 6 µM 0.268 0.093 0.084 0.106 − 0.6
Vancomycin 
8 µM
0.272 0.085 0.084 0.106 − 0.6
Metronidazole 
16 µM
0.266 0.103 0.124 0.195 − 0.2
Control 0.271 0.132 0.143 0.155 − 0.4
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5  Conclusions
This study has demonstrated that auranofin exhibits strong 
antimicrobial activity against the human pathogen C. dif-
ficile. Concentrations as low as 4.07 µg/mL were shown to 
be effective in reducing bacterial growth and vegetative cell 
viability, as well as reducing the number of spores produced 
by the bacteria. With up to 85% of the orally administered 
dose reaching the distal colon [14], it is highly likely that 
therapeutic concentrations of auranofin can be reached at the 
site of infection with a dose that is low enough to minimize 
adverse effects. In conclusion, auranofin presents a strong 
candidate as a new CDI treatment and with further investi-
gation could be considered as a therapeutic option for the 
treatment of CDI.
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Fig. 5  Number of viable vegetative cells and spores from Clostridium 
difficile cultures treated with auranofin, metronidazole, or vancomy-
cin. Vegetative cell viability assessed from C. difficile cultures at a 
12 h post-inoculation, b 24 h post-inoculation, and c 48 h post-inocu-
lation. Spore viability was assessed from C. difficile cultures at d 12 h 
post-inoculation, e 24 h post-inoculation, and f 48 h post-inoculation. 
Treatment with auranofin 4.08  mg/L is shown by filled triangles, 
treatment with metronidazole 2.74 mg/L is shown by unfilled trian-
gles, treatment with vancomycin 11.59  mg/L is shown by unfilled 
circles, and untreated cultures (control) are shown by filled squares, 
n = 3. CFU colony-forming unit
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